FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia B
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to severe hemophilia B.